# SPECIALTY GUIDELINE MANAGEMENT

# AMPYRA (dalfampridine)

## POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

<u>FDA-Approved Indication</u>: Ampyra is indicated as a treatment to improve walking in patients with multiple sclerosis. This was demonstrated by an increase in walking speed.

All other indications are considered experimental/investigational and are not covered benefits.

## **II. CRITERIA FOR INITIAL APPROVAL**

Authorization of 30 days may be granted to members with a diagnosis of multiple sclerosis if the member has sustained walking impairment (prior to initiating therapy with Ampyra).

#### **III. CONTINUATION OF THERAPY**

Authorization of 12 months may be granted to members with multiple sclerosis if the member has experienced an improvement in walking speed or other objective measure of walking ability since starting Ampyra.

#### **IV. REFERENCES**

1. Ampyra [package insert]. Ardsley, NY: Acorda Therapeutics, Inc.; September 2017.

Ampyra 1836-A SGM P2018

© 2018 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

